CAJ | 학술논문

目的：评价马来酸依那普利叶酸片用于H型高血压患者降同型半胱氨酸（ Hcy）的疗效和安全性。方法选择2011年5月至2013年8月桂林医学院附属医院收治的 H 型高血压患者107例，采用随机数字表法分为A、B、C三组，A组40例，B组33例，C组34例。 A组：马来酸依那普利（10 mg／d），＋叶酸固定复方制剂（0.8 mg／d）；B组：氨氯地平（5 mg／d）＋叶酸（0.8 mg／d）；C 组：厄贝沙坦（150 mg／d）＋叶酸（0.8 mg／d），三组患者均为口服用药，连续治疗8周。观察三组患者Hcy的变化。结果三组患者在治疗第4周、第8周 Hcy均较同组自身基线值降低，同组第8周的Hcy均较第4周Hcy降低（均P＜0.05），但A组比B组、C组降Hcy效果好。结论马来酸依那普利叶酸片对于降低H型高血压患者近期的Hcy的效果优于氨氯地平或厄贝沙坦联合叶酸的效果。
목적：평개마래산의나보리협산편용우H형고혈압환자강동형반광안산（ Hcy）적료효화안전성。방법선택2011년5월지2013년8월계림의학원부속의원수치적 H 형고혈압환자107례，채용수궤수자표법분위A、B、C삼조，A조40례，B조33례，C조34례。 A조：마래산의나보리（10 mg／d），＋협산고정복방제제（0.8 mg／d）；B조：안록지평（5 mg／d）＋협산（0.8 mg／d）；C 조：액패사탄（150 mg／d）＋협산（0.8 mg／d），삼조환자균위구복용약，련속치료8주。관찰삼조환자Hcy적변화。결과삼조환자재치료제4주、제8주 Hcy균교동조자신기선치강저，동조제8주적Hcy균교제4주Hcy강저（균P＜0.05），단A조비B조、C조강Hcy효과호。결론마래산의나보리협산편대우강저H형고혈압환자근기적Hcy적효과우우안록지평혹액패사탄연합협산적효과。
Objective To evaluate efficacy and safety of enalapril-folate acid tablets in lowering plasma homocysteine(Hcy).Methods From May 2011 to Aug.2013,a total of 107 H-type hypertensive patients in the Affiliated Hospital of Guilin Medical University were enrolled .The patients were randomly divided into three groups: enalapril ( 10 mg/d )-folate ( 0 .8 mg/d ) acid therapy as group A ( 40 cases );amlodipine (5 mg/d) and folateacid(0.8 mg/d) therapy as group B (33 cases).Irbesartan(150 mg/d) and folate acid(0.8 mg/d)therapy was considered as group C (34 cases).All patients were monitored for the change of their plasma Hcy over a period of eight weeks.Results The results indicated the plasma Hcy of all patients from three groups in the fouth and eighth week were significantly reduced compared with baseline values.The level of Hcy of patients from group A and group C in the eighth week was lower than in the fouth week (all P <0.05).Efficacy of Hcy of patients from group A was better than group B and group C. Conclusion Enalapril-folate acid tablets that can be used to reduce plasma Hcy level of H-type hyperten-sive patients safely and effectively is better than amlodipine or irbesartan combined with folate acid .